Clinical trial / 2021
In patients with knee osteoarthritis, 500 mg/day of resveratrol for 90 days improved aggrecan levels, pain, and KOOS scores, but not Coll 2-1.
An open-labeled noncontrolled clinical trial evaluated the effect of 500 mg/day oral resveratrol monotherapy for 90 days in knee osteoarthritis patients. Resveratrol administration led to a nonsignificant decrease in serum Coll 2-1 and a significant increase in serum aggrecan. Pain scores measured by VAS and KOOS significantly improved after 30 days, alongside significant improvements in all KOOS subscale areas that persisted through three months.
- Study type
- Open-labeled noncontrolled clinical trial
- Who was studied
- Patients with knee osteoarthritis (sample size not stated)
- What was measured
- Serum Coll 2-1, aggrecan, inflammation markers, safety markers, VAS, and KOOS
THE PAPER
Effect of Resveratrol on Serum Levels of Type II Collagen and Aggrecan in Patients with Knee Osteoarthritis: A Pilot Clinical Study.
Marouf BH. Biomed Res Int, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.